“nash” Archives

in
Entry Author Date Location
Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More 07/24/20 National
Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More 05/29/20 National
Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More 05/15/20 National
Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study 05/11/20 National
Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data 04/10/20 National
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data 02/24/20 San Francisco
Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate 11/08/19 National
Enanta Steps Forward in NASH Race, With Unclear Prospects 09/26/19 Boston
Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More 06/28/19 National
Conatus to Slash Staff, Consider Sale After NASH Trial Failures 06/25/19 San Diego
CymaBay Therapeutics Stumbles in NASH Race, Shares Fall 06/11/19 San Francisco
Acelity Sells to 3M in Deal Valued at $6.7 Billion, Ending IPO Plan 05/02/19 Texas
San Antonio Wound-Care Company Eyes (Another) Initial Public Offering 04/18/19 Texas
Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs 04/16/19 National
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More 04/12/19 National
Intercept Touts a Smaller Piece of Its NASH Trial at Liver Conference 04/11/19 New York
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More 03/29/19 National
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More 03/22/19 National
With New Data, Intercept On Track for First-Ever Approved NASH Drug 02/19/19 New York
With Low Expectations, Gilead’s Top NASH Drug Fails 1st Major Test 02/11/19 San Francisco
San Antonio Life Science Business Acelity Cuts 260 Jobs in Texas, NC 02/11/19 Texas
Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More 12/21/18 National
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Roche Vet O’Day Tapped to Shape Gilead’s Future as Hep C Sales Fall 12/10/18 San Francisco
Mirum Pharmaceuticals Launches with $120M to Advance Liver Drugs 11/07/18 San Diego
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More 10/12/18 National
With $45M, HotSpot Takes Drug Research to New Biological Real Estate 07/17/18 Boston
Brii Biosciences Debuts with a China Pharma Strategy Backed by $260M 05/24/18 Raleigh Durham
The Revolution in Inflammation Drug Development 05/15/18 Boston
Bio Roundup: Ex-Kiters Say Allo, NASH Cash & Data, Alkermes No & More 04/06/18 National
Page 1 of 2 next page »